Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Apimeds Pharmaceuticals UsAPUS -14.43%14 3-Year Share Buyback Ratio is -2.80 as of Mar. 2026. GuruFocus rates APUS with a GF Score™ of 14/100. The stock has 3 warning signs investors should review. Among 646 Drug Manufacturers companies, Apimeds Pharmaceuticals Us ranks worse than 54.02% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Apimeds Pharmaceuticals Us's current 3-Year Share Buyback Ratio was -2.80%.
The historical rank and industry rank for Apimeds Pharmaceuticals Us's 3-Year Share Buyback Ratio or its related term are showing as below:
APUS'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -2.8 Med: -1.4 Max: 0
Current: -2.8
During the past 5 years, Apimeds Pharmaceuticals Us's highest 3-Year Share Buyback Ratio was 0.00%. The lowest was -2.80%. And the median was -1.40%.
APUS's 3-Year Share Buyback Ratio is ranked worse than 54.02% of 646
companies
in the Drug Manufacturers industry
Industry Median: -1.9
vs APUS: -2.80
Apimeds Pharmaceuticals Us (AMEX:APUS) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Apimeds Pharmaceuticals Us 3-Year Share Buyback Ratio Related Terms
APUS vs INM, GELS, YCBD: 3-Year Share Buyback Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Apimeds Pharmaceuticals Us's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apimeds Pharmaceuticals Us 3-Year Share Buyback Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Apimeds Pharmaceuticals Us's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Apimeds Pharmaceuticals Us's 3-Year Share Buyback Ratio falls into.
Apimeds Pharmaceuticals Us 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of -2.80 mean?
Apimeds Pharmaceuticals Us (APUS) has a 3-Year Share Buyback Ratio of -2.80 as of Mar. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Apimeds Pharmaceuticals Us and its competitors. According to the industry distribution chart, Apimeds Pharmaceuticals Us ranks #349 out of 646 companies in the Drug Manufacturers industry, placing it in the top 54%.
Is Apimeds Pharmaceuticals Us' 3-Year Share Buyback Ratio too high?
Apimeds Pharmaceuticals Us' current 3-Year Share Buyback Ratio is -2.80. Based on the distribution chart, Apimeds Pharmaceuticals Us ranks #349 out of 646 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Apimeds Pharmaceuticals Us has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Apimeds Pharmaceuticals Us' 3-Year Share Buyback Ratio compare to INM and GELS?
According to the Drug Manufacturers industry distribution chart, Apimeds Pharmaceuticals Us ranks #349 out of 646 companies for 3-Year Share Buyback Ratio. This places Apimeds Pharmaceuticals Us in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Drug Manufacturers company?
A good 3-Year Share Buyback Ratio depends on the Drug Manufacturers industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Apimeds Pharmaceuticals Us and its competitors. Apimeds Pharmaceuticals Us's current 3-Year Share Buyback Ratio is -2.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apimeds Pharmaceuticals Us stock overvalued right now?
Apimeds Pharmaceuticals Us (APUS) has a current 3-Year Share Buyback Ratio of -2.80. The current 3-Year Share Buyback Ratio is -2.80. Apimeds Pharmaceuticals Us' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Apimeds Pharmaceuticals Us (APUS), the current 3-Year Share Buyback Ratio is -2.80 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Apimeds Pharmaceuticals Us Inc is a development-stage biopharmaceutical company. The Company operates its biopharmaceutical business. Its primary focus is the clinical development of Apitox, a purified honeybee venom-based drug candidate being evaluated for the treatment of pain and inflammation associated with knee osteoarthritis. The Company operates in two segments: the biopharmaceutical segment, which is focused on the clinical development of Apitox through Lokahi, and the digital asset operations segment, which encompasses the holding, sale, and advancement of the MindWaveDAO blockchain and related digital assets through MindWave.
14GF Score
Get the complete analysis for APUS
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
APUS has been successfully added to your 
